French deep-tech firm secures €5m in funding to expand regulatory certification and manufacturing of its Lyme disease and STI testing solutions.
En Carta Diagnostics has closed €5m ($6.18m) in financing to accelerate the development of its at-home molecular diagnostic platform. The round includes €3m in equity from Blue Forest Ventures, Ring Capital, and existing investors, alongside €2m in non-dilutive funding from Bpifrance and partners.
The company will use the funds to pursue regulatory approvals in Europe and the U.S., scale manufacturing via a fabless model with Circum Medical, and launch its Lyme disease detection product. En Carta is conducting clinical trials in the U.S. and Poland and holds an FDA breakthrough device designation for its Lyme solution.
En Carta also partnered with AAZ, valued at €13m, to co-develop rapid molecular tests for chlamydia and gonorrhoea in Europe, targeting commercialization in multiple markets.